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Abstract
This study will be carried out on 500 personnel divided 
into five groups: Group A:  100 cases of hepatocellular 
carcinoma without interventions. Group B: same 100 
cases of group A before and 3 months after successful 
interventions.Group C: 100 cases of established cirrhosis. 
Group D: 100 cases with chronic hepatitis C virus 
infection without established cirrhosis. Group E: 100 
healthy individuals as controls.
Methods: Sera from selected patients and controls 
have been used for estimation of SCC-Ag using CanAg 
SCC EIA. 
Results: high significant increase in serum SCCA 
level in patients with HCC (groupA and groupB) when 
compared to cirrhotic, chronic HCV and control groups 
(P < 0.001). Positive significant correlation was found 
between AFP and serum SCCA level .The best cut-off 
value to differentiate HCC patients from cirrhotic patients 
was 3.2 ng/ml for SCCA yielded with 80% sensitivity 
and 90% specificity. When combined sensitivity of both 
markers was calculated in our study at the best-chosen 
cutoff values (SCCA 3.2 ng/ml and AFP 200 ng/ml) 
sensitivity improved to 93%.
Conclusion: Combined SCCA and AFP can be used 
as in diagnosis of HCC and follow up 3 months after 
therapeutic intervention.  
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a primary malignancy 
of the liver. HCC is the fifth most common malignancy 
in the world and the third most common cause of cancer 
related deaths worldwide. It is a major health problem in 
Egypt with the incidence expected to rise continuously in 
the next decade.[1-2]
The diagnosis of liver cancer depends on both screening 
with alpha-fetoprotein (AFP) and radiological imaging 
studies. Generally, normal levels of AFP are below 10 ng/
ml but AFP greater than 200 ng/ml is suggestive of HCC 
. The sensitivity of AFP for liver cancer is about 67%; 
therefore a normal AFP does not exclude HCC. Searching 
another tumor marker, that together with AFP could 
improve the diagnostic utility of HCC.[3] 
Squamous cell carcinoma antigen (SCCA), a member 
of the high molecular weight family of serine protease 
inhibitors named serpins which are physiologically found 
in the granular layers of normal squamous epithelium 
but found to be typically expressed by neoplastic cells 
of epithelial origin in a number of different cancers 
for example cancer cervix, lung, and head and neck 
cancers hence, it can be used as a clinical marker of these 
malignancies.[4]
The structure of the serpin ovalbumin revealed the 
archetype native serpin fold that typically have three 
β-sheets (termed A, B and C) and eight or nine α-helices 
(hA-hI). Serpins also possess an exposed region termed 
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the reactive centre loop (RCL) that includes the specificity 
determining region and forms the initial interaction with 
the target protease.
Figure 1
Structure of Serine Protease Inhibitor and Squamous 
Cell Carcinoma Antigen (SCCA)
Note. a)The X-ray crystal structure of native serine protease inhibitor 
; The five-stranded A-sheet is in red, the six-stranded B-sheet in 
green, and the four-stranded C-sheet in yellow. α-helices are shown 
in cyan. The RCL is at the top of the molecule in magenta. Two 
functionally important regions of the serpin, the breach and the 
shutter, are labeled. b) The structure of squamous cell carcinoma 
antigen (SCCA).
Recently much attention has been focused on the role 
of SCCA in HCV cirrhotic patients  suggesting that high 
levels of SCCA can assess HCC development.[5]
The aim of this study was to assess the serum level 
of squamous cell carcinoma antigen (SCCA) in cirrhotic 
chronic HCV patients with and without hepatocellular 
carcinoma in relation to alfa feto protein (AFP). 
AIM OF THE WORK
The aim of this study was to assess the serum level of 
squamous cell carcinoma antigen (SCCA)  in cirrhotic 
chronic HCV patients with hepatocellular carcinoma in 
relation to alfa feto protein (AFP) .
PATIENT AND METHODS 
These groups were from both sexes who are admitted to 
the inpatient ward  and the outpatient clinic of Tropical 
Medicine Department, Faculty of Medicine, Alexandria 
University.
This study was carried out on : 
Group A:  100 cases of hepatocellular carcinoma 
without interventions. 
Group B:   same 100 cases of group A before and 3 
months after successful interventions.
Group C:  100 cases of established cirrhosis. 
Group D:   100 cases with chronic hepatitis C virus 
infection without established cirrhosis. 
Group E: 100 healthy individuals as controls.
All patients in this study were subjected to: complete 
blood picture, liver biochemical profile, serum alanine 
aminotransferase (ALT), serum aspartate aminotransferase 
(AST), serum alkaline phosphatase, total and direct serum 
bilirubin, prothrombin time and activity, serum albumin 
blood urea nitrogen(BUN), serum creatinine. Fasting 
blood sugar. Serum alpha fetoprotein (AFP).
Determination of squamous cell carcinoma antigen 
(SCC-Ag) Sera from selected patients and controls were 
used for estimation of SCC-Ag using CanAg SCC EIA. 
The CanAg SCC EIA is a solid phase, non-competitive 
immunoassay based upon the direct sandwich technique. 
Calibrators and patient samples are incubated together 
with biotinylated Anti-SCC monoclonal antibody in 
Streptavidin coated microstrips. After washing buffered 
Substrate/Chromogen reagent (hydrogen peroxide and 
3, 3’, 5, 5’ tetra-methylbenzidine) is added to each well 
and the enzyme reaction is allowed to proceed. During 
the enzyme reaction a blue colour will develop if antigen 
is present. The intensity of the colour is proportional to 
the amount of SCC present in the samples. The colour 
intensity is determined in a microplate spectrophotometer 
at 620 nm (or optionally at 405 nm after addition of Stop 
Solution). Calibration curves are constructed for each 
calibrator. The SCC concentrations of patient samples 
are the read from the calibration curve.
STATISTICAL ANALYSIS
Statistical analysis was done using the SPSS software 
package version 20.0 
Statistical analysis was done to obtain the mean, the 
standard deviation; the standard error of each mean and 
for comparison between the different groups involved 
in this study ONE WAY test was used for comparison 
between independent samples.
Arithmetic mean (X
—
) was calculated as follows:
                                X
 —
 = 
n
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Where:  X
—
= the arithmetic mean,  
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            n= the number of observations.
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Where:  X
—
1  = Arithmetic mean of the 1st group,
              X
 —
2 = Arithmetic mean of the 2nd group ,
          S.E1 = Standard error of the 1st group,  
          S.E2 = Standard error of the 2nd group.
Chi-square (X2): 
For comparison between distribution of patients 
according to different items of study and use this formula 
for calculation: 
                            ∑= EEOX
2)-(2  
O = Observed results,  E = Expected results 
(O-E)2 = Difference squared 
Where: E = 
  totalGrand
column   x totalrow Total
The probability “p” value:
It was obtained from special table for probability (p) 
value, where the degree of freedom (n1+ n2 – 2) was 
used.
Where:
n1  = Number of observations of the first group (the 
control group)
n2   = Number of observations of the second group 
(the patients group)
A “p” value of less than 0.05 was considered 
statistically significant. 
Table 1 shows a statistical significant difference 
between different studied groups regarding alpha feto 
protein (P= 0.000). 
Table 1
Comparison Between Different Studied Groups 
Regarding Alpha Feto Protein
Mean Std. deviation Minimum Maximum
Gp.  A 263.0 96.02 150. 438
Gp.  B 209.4 64.7 145. 380.
Gp.  C 154.5 48.16 75. 210.
Gp.  D 7 1.82574 5 9
Gp.  E 1.22 0.27406 0.8 1.6
F
P
38.208
0.000*
Table 2 shows a statistical significant difference 
between different studied groups regarding SCCA level 
(P= 0.000). 
Table 2 
Comparison Between Different Studied Groups 
Regarding SCCA Score
Mean Std. deviation Minimum Maximum
Gp.  A 5.53 2.16 2.5 10.
Gp.  B 5.3 1.5 3.3 7.6
Gp.  C 3.3 1.6 1.2 5.6
Gp.  D 0.824 0.15897 0.6 1.05
Gp.  E 0.646 0.23172 0.3 0.95
F
P
28.897
0.000*
Also, Positive significant correlation was found 
between AFP and SCCA in both groups 
Table 3 
Correlation Between AFP and SCCA
AFP
HCC without intervention HCC with intervention
SCCA r 0.629
* 0.525*
p <0.001 <0.001
Note. r: Pearson coefficient , *: Statistically significant at p ≤ 0.05
When combined sensitivity of both markers were 
calculated in our study at the best-chosen cutoff values 
(SCCA 3.2 ng/ml and AFP 200 ng/ml) sensitivity 
improved to 93%. (Table 4)
Table 4
AUC for AFP, SCCA and SCCA + AFP
AUC p
AFP + SCCA 0.930* 0.001
AFP 0.890* 0.003
SCCA 0.820* 0.016
DISCUSSION
In the present study patients with HCC either with or 
without therapeutic intervention  have significantly higher 
level of AFP in comparison to  chronic HCV, cirrhotic and 
control groups this is in agreement with Awadallah et al.[6] 
who reported a statistically highly significant elevation 
in the serum AFP in HCC group when compared with 
control group. Moreover, the mean serum level of AFP in 
group A (HCC before intervention) was 263 ng/ml that 
decreased to 209.4 ng/ml in group B after therapeutic 
intervention and this agreed with Feng et al[7] and Molinari 
et al.[8] Also, at AFP level of 200 ng/ml, the sensitivity was 
90%, while the specificity was 60%. 
Our results showed that SCCA level ranged from 
2.5–10 with a mean of 5.53 in HCC patients without 
interventions, 3.3–7.6 with a mean of 5.3 in patients with 
HCC with therapeutic interventions, 1.2–5.6 with a mean 
of 3.3 in cirrhotic group, 0.6–1.05 with a mean of 0.824 
in chronic HCV group while healthy control group had 
much lower values ranging from 0.3–0.95 with a mean of 
0.646. Thus, a highly significant increase in serum SCCA 
level in patients with HCC before and after therapeutic 
intervention when compared to cirrhotic, chronic HCV 
and control groups (P < 0.001). These results were 
in accordance with Hussein et al. [9] and El Ezawy et 
al.[10]  SCCA was also higher among patients with HCC 
before intervention compared to patients with HCC after 
intervention as found by Bin et al.[11] 
Applying the ROC curves analysis showed the best 
cut-off value to differentiate HCC patients from cirrhotic 
patients was 3.2 ng/ml for SCCA yielded 80% sensitivity 
and 90% specificity. These results were in agreement with 
Trevisani et al.[12]
Patients with HCC, in our study were none randomized 
selected as BCLC stage B (either one HCC lesion < 5 cm 
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in size or 3 lesions < 3 cms) so no statistical correlation 
was done between serum AFP level and tumor size.   
Our results showed a significant positive correlation 
between serum SCCA and AFP among patients with 
HCC before and after therapeutic intervention. Our data 
are in agreement with that of Hussein et al.[9] and El 
Ezawy et al.[10] who detected that SCCA were positively 
significantly correlated with AFP level.
When combined sensitivity of both markers was 
calculated in our study at the best-chosen cutoff values 
(SCCA 3.2 ng/ml and AFP 200 ng/ml) sensitivity 
improved to 93%. Matching results were found by 
Gianluigi et al.[4]
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APPENDIX:  LIST OF ABBREVIATIONS
AFP : Alpha-feto protein
AFP-L3 : Lens culinaris agglutinin-reactive fraction of AFP.
AUC : Area under the curve
HCC : Hepatocellular carcinoma.
HCV : Hepatitis C virus.
SCCA : Serum squamous cell carcinoma antigen
TACE : Transarterial chemoembolization
